This study aims to determine the reference value of HbA1c that can be used to predict adverse pregnancy outcomes. These adverse outcomes include LGA fetus, shoulder dystocia, caesarean section, pre-term birth, pre-eclampsia and fetal neonatal hypoglycaemia.
This study involves the data in our centre concerning women with gestational diabetes mellitus. The diagnosis of gestational diabetes mellitus is based on NICE guideline whereby the fasting glucose is 5.6 mol/l or more and 2 hours post glucose load 7.8 mol/l or more. The results of HbA1c and fructosamine taken during the antenatal care are documented. Outcomes of the pregnancy are documented such as antenatal complications, mode of delivery, gestational age at delivery, intrapartum and postpartum complications and neonatal complications. The results of this study is hoped to provide information on the optimum targeted levels of HbA1c and fructosamine for patients with gestational diabetes mellitus. This is the gap in knowledge in managing this cohort of patients.
Study Type
OBSERVATIONAL
Enrollment
195
Department of Obstetrics & Gynaecology, Hospital Canselor Tuanku Muhriz
Cheras, Kuala Lumpur, Malaysia
RECRUITINGTo determine the HbA1c reference value in predicting adverse pregnancy outcomes
c) To determine the HbA1c value to be used at each trimester in predicting adverse pregnancy outcomes
Time frame: Throughout study up to 1 year
To determine the prevalence of adverse pregnancy outcomes among women with GDM
Measurement of prevalent
Time frame: Throughout study up to 1 year
To assess the HbA1c value during the diagnosis of GDM and its association with adverse pregnancy outcomes
Relationship between HbA1c and adverse pregnancy outcomes
Time frame: Throughout study up to 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.